Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Esperion Therapeutics reports robust Q4 earnings, eyes global expansion

Esperion Therapeutics delivered strong financial results in Q4 2022, driven by successful formulary additions and international partner growth.
The company faces challenges in increasing brand awareness and effectively positioning bempedoic acid post statins, requiring strategic marketing and market access initiatives.
Opportunities lie in leveraging upcoming trial results for label expansion, enhancing brand visibility, and capitalizing on international growth through partnerships.

Esperion Therapeutics excels in Q1 2023, poised for market opportunities

Esperion Therapeutics delivered robust Q1 results with revenue growth and positive market reactions to its studies. While facing legal challenges and operational discussions, the company is well-positioned to leverage opportunities in the market through its strong partnerships and financial stability.

Esperion Therapeutics excels in Q2 earnings, eyes label expansion opportunities

Esperion Therapeutics delivered strong financial performance in Q2 2023, driven by revenue growth, cost management, and strategic partnerships.
While facing challenges in managing expenses, the company is well-positioned to capitalize on market opportunities post-label expansion approvals.
With a solid cash position, ongoing operational efficiency efforts, and a focus on growth initiatives, Esperion is poised for continued success.
The company's commitment to innovation and patient outcomes bodes well for its future growth trajectory and market competitiveness.

Esperion Therapeutics excels in Q3 earnings amidst regulatory hurdles

Esperion Therapeutics delivered strong financial results in Q3 2023, driven by revenue growth and strategic collaborations, despite facing regulatory and litigation challenges.
The company's focus on expanding market presence through FDA approvals and international expansion presents promising growth avenues for future success.
With a solid financial position and ongoing initiatives to drive prescription growth, Esperion is poised to capitalize on market opportunities and navigate challenges effectively.

Esperion Therapeutics reports robust Q4 earnings and eyes market expansion

Esperion Therapeutics delivered strong financial performance in Q4 2023, showcasing significant revenue growth and strategic advancements.
While facing challenges in managing expenses and executing growth strategies, the company is well-positioned to capitalize on market opportunities and drive future expansion.
With a clear roadmap for expense management and a focus on product reach and market expansion, Esperion is poised for continued growth and value creation for stakeholders.
The settlement agreement and label expansion approvals provide a solid foundation for Esperion to leverage opportunities, overcome challenges, and drive sustainable growth.

Esperion Therapeutics posts robust Q1 results amid FDA label wins

Esperion Therapeutics delivered strong financial performance in Q1 2024, driven by revenue growth and FDA label expansions.
The company faces challenges in maintaining prescription growth and navigating payer dynamics post-label update.
Strategic initiatives and market opportunities present avenues for Esperion to capitalize on its recent successes and drive future growth.

Esperion Therapeutics reports robust Q2 revenue growth and global expansion

Esperion Therapeutics delivered strong financial performance in Q2 2024, driven by revenue growth and successful market expansion efforts.
While facing challenges such as debt extinguishment losses and high operating expenses, the company capitalized on opportunities for international growth and product marketability.
By leveraging strengths in expanded product labels and improved market access, Esperion is poised to navigate challenges and capitalize on growth opportunities in the pharmaceutical sector.

Esperion Therapeutics reports robust Q3 performance and eyes global expansion

Esperion Therapeutics delivered strong financial performance in Q3 2024, driven by revenue growth and strategic initiatives to expand market access and product offerings.
While challenges in achieving profitability persist, the company's focus on innovation, global expansion, and operational efficiency underscores its long-term growth potential.
By leveraging strengths in collaboration, research, and market differentiation, Esperion is poised to capitalize on opportunities for further international expansion and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

ANN ARBOR, Mich., Nov.  17, 2019  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia. Bempedoic acid is being developed as a convenient, once-daily, oral therapy for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) added onto maximally tolerated statin therapy. Bempedoic acid and the bempedoic acid 180 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets’ new drug applications (NDAs) are currently under regulatory review by the U.S. Food and Drug Administration (FDA) and the marketing authorisation applications (MAAs) are currently under centralized review by the European Medicines Agency (EMA).

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

 –  Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP –   –    Over 52- Weeks,  Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo –   – Bempedoic Acid is being developed as an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol –   – Research by Anne C. Goldberg, MD, FACP, FAHA, FNLA published in the Journal of the American Medical Association –

Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

Esperion Therapeutics (ESPR) reports mixed third-quarter results.

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

ANN ARBOR, Mich., Oct.  25, 2019  (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23rd. The Summit was comprised of a panel of physicians and scientists assembled to assess innovations and medicines that have the potential to enhance healthcare in the coming year. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List

Esperion Therapeutics, owner of bempedoic acid (BA), aims to reduce LDL-C in statin-resistant/intolerant patients. BAs potential is massive considering the safety and efficacy data to date & size of market.

Esperion Therapeutics: Low Risk And Primed For Substantial Growth

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Esperion Therapeutics (ESPR) Down 10.8% Since Last Earnings Report: Can It Rebound?

– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial –  – Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 –

Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid

A combination regimen of Esperion (ESPR) and Merck's Zetia significantly improves bad cholesterol (LDL-C) levels in patients with both hypercholesterolemia and type II diabetes.

Esperion's Bempedoic Acid Succeeds in Phase II Diabetes Study

— Bempedoic Acid / Ezetimibe  Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —  — Provided 25% hsCRP Reduction —  — No Worsening of Glycemic Control —  — Overall Adverse Events Comparable to Placebo —  — Conference Call and Webcast on  Thursday , August 29 at 8:00 a.m. Eastern Time —

Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes

Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo therapy seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize launch.

Esperion's Drugs in Review Hold Potential, Funds a Concern

Esperion Therapeutics (ESPR) reports mixed second-quarter results.

Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat

President & CEO of Esperion Therapeutics Inc (30-Year Financial, Insider Trades) Timothy M Mayleben (insider trades) bought 5,000 shares of ESPR on 08/01/2019 at an average price of $39.56 a share.

Esperion Therapeutics Inc (ESPR) President & CEO Timothy M Mayleben Bought $197,800 of Shares

AXA Equitable Holdings Inc

Karuna Therapeutics Inc

Liberty Latin America Ltd.

Liberty Latin America

Details the CEO buys this past week for the following companies: AXA Equitable Holdings, Liberty Latin America, Karuna Therapeutics, Esperion Therapeutics and Altus Midstream

Weekly CEO Buys Highlight (July 7)

BioMarin Pharmaceutical

CommScope Hld

Halliburton

Lam Research

Sarepta Therapeutics

WPX Energy

With the three major stock indexes trading at or near all-time highs, many investors are scratching their heads about where to look for new investment ideas at a time when interest rates have become so low again.

Credit Suisse Best Ideas List Still Has 50% Implied Upside for These Stocks

Esperion Therapeutics (ESPR) Down 5.6% Since Last Earnings Report: Can It Rebound?

Clovis Oncology

Clovis Oncology and Esperion Therapeutics stocks skidded Wednesday after an analyst downgraded the biotech companies to sell ratings amid rising competition in their respective markets.

Biotech Stocks Clobbered As Two Slammed With Sell Ratings

FDA accepted New Drug Applications from Esperion for bempedoic acid and bempedoic acid/ezetimibe combination tablet to treat elevated low-density lipoprotein cholesterol (bad cholesterol).

Esperion Is The One To Watch, After FDA Deems Advisory Panel Is Not Needed

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 132.58% and 53.20%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Surpass Estimates

The company is one step closer to securing an OK for its new cholesterol-busting drug.

Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today

Esperion popped early Monday after the Food and Drug Administration accepted its applications for a pair of cholesterol treatments called bempedoic acid and bempedoic acid plus ezetimibe.

A Single Rival Caused 2 Biopharma Stocks To Slip — Here's Why

Shares of small-cap biotech Esperion Therapeutics Inc. were rallying Monday after the company received good news from the DFA.

News for Esperion Therapeutics Stock (ESPR)